MetaVia (MTVA)
NASDAQ:MTVA
Want to see MTVA full AI Analyst Report?
Top Page
MetaVia
(NASDAQ:MTVA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▲(7.14% Upside)
Action:ReiteratedDate:04/11/26
The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses, and continued cash burn with equity erosion) and bearish technicals (below key moving averages with negative MACD). Corporate events provide some support via positive clinical progress and added funding, but valuation remains constrained by losses and the absence of a dividend.
Positive Factors
Clinical Progress — DA-1726 Part 3 Dosed
Dosing the first Part 3 patient materially de-risks development timing and regulatory path for DA-1726. Successful completion could validate higher-dose safety/tolerability, support later-stage designs and strengthen bargaining power with partners or licensors over the next 6–18 months.
Negative Factors
No Revenue; Ongoing Losses
Absence of product revenue makes the company fully dependent on external financing until commercialization. Persistent net losses mean value creation hinges entirely on successful trials or partner deals, raising execution risk and lengthening the timeline to self-sustaining operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Progress — DA-1726 Part 3 Dosed
Dosing the first Part 3 patient materially de-risks development timing and regulatory path for DA-1726. Successful completion could validate higher-dose safety/tolerability, support later-stage designs and strengthen bargaining power with partners or licensors over the next 6–18 months.
Read all positive factors
MetaVia (MTVA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.94M
Dividend YieldN/A
Average Volume (3M)3.42M
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue GrowthN/A
EPS Growth80.73%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.01
Shares Outstanding5,090,936
10 Day Avg. Volume118,677
30 Day Avg. Volume3,419,960
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.95
Enterprise Value/Market Cap-0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit469.12
Enterprise Value/Ebitda0.49
Forecast
1Y Price Target
$14.00Price Target Upside900.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.97
Revenue Forecast (FY)N/A
MetaVia Business Overview & Revenue Model
Company Description
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionalit...
MetaVia Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -19.00K | -24.00K | -7.00K | -28.00K | -72.00K |
| EBITDA | -13.69M | -28.79M | -15.88M | -11.76M | -15.24M |
| Net Income | -12.97M | -27.59M | -12.47M | -13.97M | -15.28M |
Balance Sheet | |||||
| Total Assets | 69.12M | 16.26M | 22.78M | 33.53M | 16.80M |
| Cash, Cash Equivalents and Short-Term Investments | 10.28M | 16.02M | 22.43M | 33.36M | 16.39M |
| Total Debt | 210.00K | 136.00K | 203.00K | 0.00 | 71.00K |
| Total Liabilities | 63.79M | 8.33M | 6.10M | 11.78M | 2.20M |
| Stockholders Equity | 5.33M | 7.93M | 16.68M | 21.75M | 14.60M |
Cash Flow | |||||
| Free Cash Flow | -15.70M | -24.72M | -10.85M | -11.71M | -15.14M |
| Operating Cash Flow | -15.70M | -24.71M | -10.80M | -11.71M | -15.13M |
| Investing Cash Flow | -2.00K | -8.00K | -50.00K | 8.00K | -586.00K |
| Financing Cash Flow | 9.96M | 18.30M | -80.00K | 28.68M | 22.03M |
MetaVia Technical Analysis
Neutral
1.40
Price Trends
1.48
Negative
4.15
Negative
6.53
Negative
Market Momentum
-0.08
Negative
45.84
Neutral
55.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTVA, the sentiment is Neutral. The current price of 1.4 is above the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.48, and below the 200-day MA of 6.53, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 45.84 is Neutral, neither overbought nor oversold. The STOCH value of 55.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MTVA.
MetaVia Risk Analysis
MetaVia disclosed 67 risk factors in its most recent earnings report. MetaVia reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
MetaVia Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $45.65M | -3.44 | -16.25% | ― | 34.91% | 84.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $24.19M | -0.30 | 9999.00% | ― | ― | -5368.40% | |
48 Neutral | $17.23M | -0.51 | -54.40% | ― | ― | 50.13% | |
45 Neutral | $7.94M | -2.52 | -229.48% | ― | ― | 80.73% |
* Healthcare Sector Average
MTVA
MetaVia
1.59
-7.11
-81.72%
PMN
ProMIS Neurosciences
11.10
-3.98
-26.38%
CTXR
Citius Pharmaceuticals
0.69
-0.15
-18.13%
RLYB
Rallybio
8.78
6.45
276.82%
KAPA
Kairos Pharma, Ltd.
0.60
-0.24
-28.86%
MetaVia Corporate Events
Business Operations and StrategyProduct-Related Announcements
MetaVia Advances DA-1726 Obesity Trial With First Patient
Positive
Apr 10, 2026
On April 10, 2026, MetaVia Inc. announced it had dosed the first patient in Part 3 of its Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog targeting GLP-1 and glucagon receptors for the treatment of obesity. The new 16-week study seg...
Business Operations and Strategy
MetaVia Updates Investor Strategy for Obesity and MASH
Positive
Mar 26, 2026
On March 26, 2026, MetaVia Inc. reported that it had posted an updated investor presentation outlining its strategy to address obesity and MASH, two large and rapidly expanding therapeutic markets with projected annual sales in the tens of billion...
Business Operations and StrategyProduct-Related Announcements
MetaVia Advances DA-1726 Obesity Drug into Phase 1 Part 3
Positive
Mar 18, 2026
On March 18, 2026, MetaVia Inc. announced that an Institutional Review Board at Clinical Pharmacology of Miami approved Part 3 of its Phase 1 clinical trial for DA-1726, its lead GLP-1 and glucagon dual agonist for obesity. The new 16-week study w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.